

Kay Ka-Wai Li

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2197426/publications.pdf>

Version: 2024-02-01

34
papers

966
citations

430874

18
h-index

454955

30
g-index

36
all docs

36
docs citations

36
times ranked

1849
citing authors

#	ARTICLE	IF	CITATIONS
1	Adult IDH wild-type lower-grade gliomas should be further stratified. <i>Neuro-Oncology</i> , 2017, 19, 1327-1337.	1.2	177
2	TERT promoter mutations contribute to subset prognostication of lower-grade gliomas. <i>Modern Pathology</i> , 2015, 28, 177-186.	5.5	107
3	IDH mutant lower grade (WHO Grades II/III) astrocytomas can be stratified for risk by CDKN2A, CDK4 and PDGFRA copy number alterations. <i>Brain Pathology</i> , 2020, 30, 541-553.	4.1	73
4	miR-383 is Downregulated in Medulloblastoma and Targets Peroxiredoxin 3 (PRDX3). <i>Brain Pathology</i> , 2013, 23, 413-425.	4.1	71
5	Loss of CIC and FUBP1 expressions are potential markers of shorter time to recurrence in oligodendroglial tumors. <i>Modern Pathology</i> , 2014, 27, 332-342.	5.5	45
6	Biomarker-based prognostic stratification of young adult glioblastoma. <i>Oncotarget</i> , 2016, 7, 5030-5041.	1.8	45
7	Combination genetic signature stratifies lower-grade gliomas better than histological grade. <i>Oncotarget</i> , 2015, 6, 20885-20901.	1.8	42
8	MIR-137 Suppresses Growth and Invasion, is Downregulated in Oligodendroglial Tumors and Targets CSE1L. <i>Brain Pathology</i> , 2013, 23, 426-439.	4.1	39
9	miR-106b is overexpressed in medulloblastomas and interacts directly with PTEN. <i>Neuropathology and Applied Neurobiology</i> , 2015, 41, 145-164.	3.2	37
10	Pediatric low-grade gliomas can be molecularly stratified for risk. <i>Acta Neuropathologica</i> , 2018, 136, 641-655.	7.7	36
11	Radiomic Features From Multi-Parameter MRI Combined With Clinical Parameters Predict Molecular Subgroups in Patients With Medulloblastoma. <i>Frontiers in Oncology</i> , 2020, 10, 558162.	2.8	34
12	Clinical and mutational profiles of adult medulloblastoma groups. <i>Acta Neuropathologica Communications</i> , 2020, 8, 191.	5.2	30
13	The kinesin KIF14 is overexpressed in medulloblastoma and downregulation of KIF14 suppressed tumor proliferation and induced apoptosis. <i>Laboratory Investigation</i> , 2017, 97, 946-961.	3.7	24
14	Medulloblastoma in China: Clinicopathologic Analyses of SHH, WNT, and Non-SHH/WNT Molecular Subgroups Reveal Different Therapeutic Responses to Adjuvant Chemotherapy. <i>PLoS ONE</i> , 2014, 9, e99490.	2.5	24
15	Incremental prognostic value and underlying biological pathways of radiomics patterns in medulloblastoma. <i>EBioMedicine</i> , 2020, 61, 103093.	6.1	23
16	Not all 1p/19q non-codeleted oligodendroglial tumors are astrocytic. <i>Oncotarget</i> , 2016, 7, 64615-64630.	1.8	22
17	Identification of subsets of IDH-mutant glioblastomas with distinct epigenetic and copy number alterations and stratified clinical risks. <i>Neuro-Oncology Advances</i> , 2019, 1, vdz015.	0.7	22
18	Molecular landscape of IDH-mutant primary astrocytoma Grade IV/glioblastomas. <i>Modern Pathology</i> , 2021, 34, 1245-1260.	5.5	21

#	ARTICLE	IF	CITATIONS
19	Dual degradation signals destruct GLI1: AMPK inhibits GLI1 through \hat{I}^2 -TrCP-mediated proteasome degradation. <i>Oncotarget</i> , 2017, 8, 49869-49881.	1.8	20
20	Signaling pathway and molecular subgroups of medulloblastoma. <i>International Journal of Clinical and Experimental Pathology</i> , 2013, 6, 1211-22.	0.5	18
21	CRMP1 Inhibits Proliferation of Medulloblastoma and Is Regulated by HMGA1. <i>PLoS ONE</i> , 2015, 10, e0127910.	2.5	13
22	Whole-exome sequencing revealed mutational profiles of giant cell glioblastomas. <i>Brain Pathology</i> , 2019, 29, 782-792.	4.1	11
23	Clinicopathological analysis of UHRF1 expression in medulloblastoma tissues and its regulation on tumor cell proliferation. <i>Medical Oncology</i> , 2016, 33, 99.	2.5	10
24	Molecular subgrouping of medulloblastoma based on few-shot learning of multitasking using conventional MR images: a retrospective multicenter study. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa079.	0.7	5
25	Molecular landscape of pediatric type IDH wildtype, H3 wildtype hemispheric glioblastomas. <i>Laboratory Investigation</i> , 2022, 102, 731-740.	3.7	5
26	Combinations of Single-Gene Biomarkers Can Precisely Stratify 1,028 Adult Gliomas for Prognostication. <i>Frontiers in Oncology</i> , 2022, 12, 839302.	2.8	3
27	Oligodendrogliomas in pediatric and teenage patients only rarely exhibit molecular markers and patients have excellent survivals. <i>Journal of Neuro-Oncology</i> , 2018, 139, 307-322.	2.9	2
28	Low-grade BRAF V600E mutant oligodendroglioma-like tumors of children may show EGFR and MET amplification. <i>Brain Pathology</i> , 2021, 31, 211-214.	4.1	2
29	Expanding the clinical and molecular spectrum of pituitary blastoma. <i>Acta Neuropathologica</i> , 2022, 143, 415-417.	7.7	2
30	Mismatch repair proteins PMS2 and MLH1 can further refine molecular stratification of IDH-mutant lower grade astrocytomas. <i>Clinical Neurology and Neurosurgery</i> , 2021, 208, 106882.	1.4	1
31	An Unusual Combination of Mirror-Image Dextrocardia with Familial Medulloblastoma: Is There a Histogenetic Relationship?. <i>World Neurosurgery</i> , 2017, 107, 860-867.	1.3	0
32	MEDU-05. PROGNOSTIC IMPLICATION OF TERT PROMOTER MUTATION AND TP53 NUCLEAR STAINING IN ADULT MEDULLOBLASTOMA. <i>Neuro-Oncology</i> , 2019, 21, ii104-ii104.	1.2	0
33	Molecular landscape of IDH-wildtype, H3-wildtype glioblastomas of adolescents and young adults. <i>Neuropathology and Applied Neurobiology</i> , 2022, 48, .	3.2	0
34	RARE-06. Expanding the clinical and molecular spectrum of pituitary blastoma. <i>Neuro-Oncology</i> , 2022, 24, i10-i10.	1.2	0